Where Do We (INDI)GO From Here?
-
Published:2024-02
Issue:2
Volume:118
Page:330-333
-
ISSN:0360-3016
-
Container-title:International Journal of Radiation Oncology*Biology*Physics
-
language:en
-
Short-container-title:International Journal of Radiation Oncology*Biology*Physics
Author:
Kinslow Connor J.ORCID,
Brown Paul D.,
Iwamoto Fabio M.,
Wu Cheng-Chia,
Yu James B.,
Cheng Simon K.,
Wang Tony J.C.ORCID
Reference24 articles.
1. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma;Mellinghoff;N Engl J Med,2023
2. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma;Buckner;N Engl J Med,2016
3. Phase 2 study of a temozolomide-based chemoradiation therapy regimen for high-risk, low-grade gliomas: Long-term results of Radiation Therapy Oncology Group 0424;Fisher;Int J Radiat Oncol Biol Phys,2020
4. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): A randomised, open-label, phase 3 intergroup study;Reijneveld;Lancet Oncol,2016
5. MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas;Kinslow;Clin Cancer Res,2023
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献